文献速递角膜与眼表疾病

0.55%盐酸半胱胺滴眼液治疗胱氨酸病患者的长期随访

Long-term follow-up of cystinosis patients treated with 0.55% cysteamine hydrochloride.
PubMed 文献 · Br J Ophthalmol · 2020-06-27

该研究回顾性分析了法国130例接受Cystadrops(0.55%盐酸半胱胺粘性溶液)治疗的胱氨酸病患者,随访长达45个月,发现患者视力维持正常水平,角膜胱氨酸结晶评分随时间下降并在约27个月后稳定,畏光在3个月内改善,安全性与耐受性良好。

要点

  • 长期使用Cystadrops可维持胱氨酸病患者正常视力并减少角膜结晶。
  • 畏光在治疗3个月内明显改善并趋于稳定。
  • 不良事件多为短暂刺激、刺痛或视物模糊,严重事件可能与原发病相关。

核心结论

  • Cystadrops在真实临床实践中对胱氨酸病患者显示出疗效、安全性和耐受性。

研究设计与样本

  • 回顾性分析法国2013至2017年临时使用授权队列中130例接受Cystadrops治疗的患者。

主要发现

  • 患者平均每眼每日滴注3.3(±0.94)次。
  • 随访至45个月,患者视力评分维持0.0,接近正常。
  • 角膜胱氨酸结晶评分随时间下降,约27个月后稳定在1.22至1.87之间。
  • 畏光在3个月内减轻,稳定在约1.5和1.7分。
  • 报告47例非严重不良反应,多为短暂刺激、刺痛或视物模糊;4例严重不良事件包括角膜炎和角膜溃疡,可能由原发病引起。

临床怎么用

  • 对于胱氨酸病患者,可考虑长期使用0.55%盐酸半胱胺滴眼液以控制角膜结晶和畏光。

局限性

  • 研究为回顾性设计,缺乏对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: Cystinosis is a rare, autosomal recessive disorder causing defective transport of cystine out of lysosomes. Cystadrops (0.55% cysteamine hydrochloride in viscous solution) has been used on a named-patient basis to treat the accumulation of cystine crystals in the cornea in patients with cystinosis. METHODS: Retrospective analysis of the Temporary Authorisation for Use cohort of 130 patients who received Cystadrops between 2013 and 2017 in France. RESULTS: Patients received an average dosage of 3.3 (±0.94) instillations per eye per day. Over the duration of follow-up, of up to 45 months, patients maintained visual acuity scores of 0.0, which approximated normal. Corneal cystine crystal scores tended to decrease over time, stabilising after around 27 months between 1.22 and 1.87. Photophobia decreased within 3 months, stabilising on scores of around 1.5 and 1.7. 47 non-serious adverse reactions were reported, which were generally transient irritation, stinging or blurred vision. Four serious adverse events were reported, including keratitis and corneal ulcer, but these may have been caused by the underlying disease. CONCLUSION: This large safety cohort confirms the efficacy, safety and tolerability of Cystadrops in real-world clinical practice.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Liang H, Labbé A, Baudouin C, et al. Long-term follow-up of cystinosis patients treated with 0.55% cysteamine hydrochloride. Br J Ophthalmol. 2020. PMID: 32593979. doi:10.1136/bjophthalmol-2020-316450

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。